Muscular Dystrophy Association   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: New York NY United States (1950)

Organization Overview

First Clinical Trial
2000
NCT00005674
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Muscular Dystrophy Association

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Charcot-Marie-Tooth Disease (Phase 3)

Hereditary Sensory and Motor Neuropathy (Phase 3)

Motor Neuron Disease (Phase 2)

Muscle Weakness (Phase 1)

Muscular Dystrophies (Phase 4)

Muscular Dystrophies, Limb-Girdle (Phase 1)

Muscular Dystrophy, Duchenne (Phase 4)

Myasthenia Gravis (Phase 1)

Myotonic Dystrophy (Phase 2)

Nerve Compression Syndromes (Phase 3)

Sarcoglycanopathies (Phase 1)

Sclerosis (Phase 2)

Tooth Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 14